InsiderTrades.com logo
Paul L. Berns net worth and biography
  • Phone
  • Email
  • Website

Paul Berns Biography and Net Worth

Director of Kardigan

Paul brings over 30 years of pharmaceutical and biotechnology expertise and is currently a managing director of ARCH Venture Partners, which he joined in 2018. He is also co-founder and executive chairman of Neumora Therapeutics, chairman for Happy AI and NICO Therapeutics, and a member of the boards of Mirador Therapeutics, Areteia Therapeutics, Metsera Therapeutics, Epirium, Ollin Biosciences and Unity Biotechnology. Paul previously served as president, CEO and chairman at Anacor Pharmaceuticals (acquired by Pfizer), president and CEO of Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and Bone Care International (acquired by Genzyme), as well as co-founder and chairman of HI-Bio (acquired by Biogen). Paul has also held senior management roles at Abbott Laboratories, BASF Pharmaceuticals/Knoll (acquired by Abbott) and Bristol Myers Squibb. Paul previously served on the boards of EQRX, Jazz Pharmaceuticals, PLC, MC2 Therapeutics, Menlo Therapeutics, XenoPort, Allos Therapeutics and Bone Care International. He holds a B.S. in Economics from the University of Wisconsin.

What is Paul L. Berns' net worth?

The estimated net worth of Paul L. Berns is at least $328.07 million as of June 22nd, 2026. Berns owns 15,042,035 shares of Kardigan stock worth more than $328,066,783 as of August 13th. This net worth estimate does not reflect any other investments that Berns may own. Learn More about Paul L. Berns' net worth.

How do I contact Paul L. Berns?

The corporate mailing address for Berns and other Kardigan executives is 506 Carnegie Center Drive Suite 201, Princeton, NJ 08540, US. Kardigan can also be reached via phone at 415-573-3220 and via email at [email protected]. Learn More on Paul L. Berns' contact information.

Has Paul L. Berns been buying or selling shares of Kardigan?

Paul L. Berns has not been actively trading shares of Kardigan over the course of the past ninety days. Most recently, on Monday, June 22nd, Paul L. Berns bought 1,250,000 shares of Kardigan stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $20,000,000.00. Following the completion of the transaction, the director now directly owns 15,042,035 shares of the company's stock, valued at $240,672,560. Learn More on Paul L. Berns' trading history.

Are insiders buying or selling shares of Kardigan?

In the last year, Kardigan insiders bought shares 2 times. They purchased a total of 2,500,000 shares worth more than $40,000,000.00. The most recent insider tranaction occured on June, 22nd when Director Paul L Berns bought 1,250,000 shares worth more than $20,000,000.00. Learn More about insider trades at Kardigan.

Information on this page was last updated on 6/22/2026.

Paul L. Berns Insider Trading History at Kardigan

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/22/2026Buy1,250,000$16.00$20,000,000.0015,042,035View SEC Filing Icon  
See Full Table

Paul L. Berns Buying and Selling Activity at Kardigan

This chart shows Paul L Berns's buying and selling at Kardigan by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kardigan Company Overview

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.
Read More

Today's Range

Now: $21.81
Low: $21.43
High: $22.58

50 Day Range

MA: N/A

2 Week Range

Now: $21.81
Low: $16.25
High: $27.00

Volume

216,746 shs

Average Volume

383,175 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A